Chief Executive Officer, Cambridge Technologies
BS., California Polytechnic University; Ph.D., Veterinary Microbiology, University of Minnesota; 2001 Recipient, Distinguished Research Award, University of Minnesota
Dr. Simonson began his career as a scientist for Salsbury Laboratories, becoming the Manager of Biological Development. He served as Manager of Biologic Development for Solvay before moving to Oxford Laboratories, first as Team Manager licensing the original swine biologics line for the company and later becoming Vice President of Research and Development. After Oxford was purchased by The Upjohn Company, he became the Director of Biological Development Worldwide. Following the purchase of Upjohn by Bayer, he advanced to Director of Biologics Project Management Worldwide. Dr. Simonson comes to Cambridge Technologies from Newport Laboratories, where he was the Chief Operating Officer and later President. He has authored numerous publications and patents regarding biologic research and product applications, and is often requested as a speaker and presenter at both domestic and international technical meetings.